Association between total type I collagen N-terminal propeptide and coronary artery disease risk score in the general Japanese population.
Bone-type alkaline phosphatase
Brachial–ankle pulse wave velocity
Suita score
cross-linked N-telopeptide of type 1 collagen
intact Parathyroid hormone
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
16
02
2022
revised:
09
05
2022
accepted:
13
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Bone metabolic dysregulation plays an important role in the pathogenesis of atherosclerosis; however, whether its markers contribute to coronary artery disease (CAD) risk in the general population remains unclear. Therefore, this study aimed to analyze the association between bone metabolic markers and CAD risk score in the general Japanese population. The Iwate Medical Megabank Organization collected individual participant data during a community-based cohort study in the Iwate prefecture (n = 5,095, age = 58.9 ± 12.4 years). Participants with osteoporosis, chronic kidney disease, malignant disease, or primary wasting disease were excluded from the study. The present study measured the levels of circulating bone metabolic markers, including total type I collagen N-terminal propeptide (TP1NP), bone-type alkaline phosphatase, cross-linked N-telopeptide of type 1 collagen (NTX), and intact parathyroid hormone. CAD risk and atherosclerosis were evaluated using the Suita score and brachial-ankle pulse wave velocity (baPWV) measurement, respectively. Among the bone metabolic markers, TP1NP was strongly associated with a high Suita score (≥56 points) (OR = 0.77, 95% CI = 0.69-0.82, P < 0.001). When participants were divided into quartiles of TP1NP levels, the subgroup with the lowest TP1NP level was associated with a high Suita score (≥56 points) and high baPWV (>1,400 cm/s). This study demonstrated that TP1NP levels decreased in participants with high Suita scores and high baPWV, suggesting that TP1NP downregulation may indicate future CAD risk and atherosclerosis progression in the general Japanese population.
Sections du résumé
Background
UNASSIGNED
Bone metabolic dysregulation plays an important role in the pathogenesis of atherosclerosis; however, whether its markers contribute to coronary artery disease (CAD) risk in the general population remains unclear. Therefore, this study aimed to analyze the association between bone metabolic markers and CAD risk score in the general Japanese population.
Methods
UNASSIGNED
The Iwate Medical Megabank Organization collected individual participant data during a community-based cohort study in the Iwate prefecture (n = 5,095, age = 58.9 ± 12.4 years). Participants with osteoporosis, chronic kidney disease, malignant disease, or primary wasting disease were excluded from the study. The present study measured the levels of circulating bone metabolic markers, including total type I collagen N-terminal propeptide (TP1NP), bone-type alkaline phosphatase, cross-linked N-telopeptide of type 1 collagen (NTX), and intact parathyroid hormone. CAD risk and atherosclerosis were evaluated using the Suita score and brachial-ankle pulse wave velocity (baPWV) measurement, respectively.
Results
UNASSIGNED
Among the bone metabolic markers, TP1NP was strongly associated with a high Suita score (≥56 points) (OR = 0.77, 95% CI = 0.69-0.82, P < 0.001). When participants were divided into quartiles of TP1NP levels, the subgroup with the lowest TP1NP level was associated with a high Suita score (≥56 points) and high baPWV (>1,400 cm/s).
Conclusions
UNASSIGNED
This study demonstrated that TP1NP levels decreased in participants with high Suita scores and high baPWV, suggesting that TP1NP downregulation may indicate future CAD risk and atherosclerosis progression in the general Japanese population.
Identifiants
pubmed: 35620659
doi: 10.1016/j.ijcha.2022.101056
pii: S2352-9067(22)00105-1
pmc: PMC9127151
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101056Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Clin Endocrinol Metab. 2012 May;97(5):1737-44
pubmed: 22399511
Mod Rheumatol. 2011 Dec;21(6):608-20
pubmed: 21512822
J Epidemiol. 2016 Sep 5;26(9):493-511
pubmed: 27374138
Nephrol Dial Transplant. 2006 Dec;21(12):3435-42
pubmed: 17005530
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
Eur J Endocrinol. 2017 Mar;176(3):R137-R157
pubmed: 28049653
J Bone Miner Res. 2006 Apr;21(4):549-55
pubmed: 16598375
J Bone Miner Res. 2000 Aug;15(8):1537-44
pubmed: 10934652
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Front Cell Dev Biol. 2020 Feb 07;8:57
pubmed: 32117983
J Clin Endocrinol Metab. 1996 Sep;81(9):3366-71
pubmed: 8784098
J Atheroscler Thromb. 2014;21(8):784-98
pubmed: 24671110
Adv Ther. 2021 Aug;38(8):4246-4257
pubmed: 34165700
Hypertension. 1999 May;33(5):1111-7
pubmed: 10334796
Diabetol Int. 2018 Mar 27;9(1):1-45
pubmed: 30603347
Eur Heart J. 2018 Feb 14;39(7):508-579
pubmed: 29190377
Osteoporos Int. 2017 Sep;28(9):2645-2652
pubmed: 28555285
Calcif Tissue Int. 2008 May;82(5):341-7
pubmed: 18470550
J Clin Endocrinol Metab. 2004 Aug;89(8):3651-5
pubmed: 15292281
J Bone Miner Metab. 2001;19(6):331-7
pubmed: 11685647
Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):927-939
pubmed: 30665553
J Bone Miner Res. 1999 Jul;14(7):1203-10
pubmed: 10404022
J Epidemiol. 2021 Jan 5;31(1):65-76
pubmed: 31932529
J Bone Miner Res. 2005 Nov;20(11):1912-20
pubmed: 16234963
Biomolecules. 2018 Jun 15;8(2):
pubmed: 29914099
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1078-1093
pubmed: 32237904
J Clin Endocrinol Metab. 2015 Oct;100(10):3934-42
pubmed: 26308289
Hypertens Res. 2003 Aug;26(8):615-22
pubmed: 14567500
Hypertens Res. 2002 May;25(3):359-64
pubmed: 12135313
Clin Chim Acta. 2019 Nov;498:101-107
pubmed: 31425674
Osteoporos Int. 2019 Sep;30(9):1807-1815
pubmed: 31190121
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
Int J Mol Sci. 2020 Sep 18;21(18):
pubmed: 32961953